Core Viewpoint - The document outlines the internal control system of Beijing Beilu Pharmaceutical Co., Ltd., emphasizing the importance of compliance, efficiency, asset security, and accurate information disclosure to protect investors' rights and ensure the company's healthy development [1][2]. Summary by Sections General Principles - The internal control system aims to provide reasonable assurance for compliance with laws, operational efficiency, asset security, and accurate information disclosure [1]. - The company must develop its internal control system based on its operational characteristics and environment, adhering to relevant regulations [1][2]. Basic Requirements for Internal Control - The company is responsible for establishing a robust internal control system to ensure legal operations and scientific decision-making [2]. - Clear definitions of goals, responsibilities, and authority for each department and position are essential [2][3]. - Internal control activities should cover all business segments related to financial reporting and information disclosure [2][3]. Management Control of Subsidiaries - The company must establish control policies for its subsidiaries, ensuring they develop their internal control systems [7]. - Regular analysis of subsidiaries' financial reports and performance is required to maintain oversight [7]. Internal Control of Related Transactions - A robust internal control system for related transactions must be established, ensuring fairness and transparency [8][9]. - Related transactions must be disclosed and approved by independent directors before board review [8][9]. External Guarantee Internal Control - The company must adhere to legal and prudent principles when providing external guarantees, ensuring risk control [10][11]. - Approval processes for external guarantees must be clearly defined in the company's articles of association [10][11]. Use of Raised Funds Internal Control - The management of raised funds should follow principles of regulation, safety, efficiency, and transparency [15][16]. - Strict approval processes for the use of raised funds must be established, ensuring compliance with the investment plan [15][16]. Major Investment Internal Control - Major investments must be approved by the board or shareholders, with a focus on risk control and investment effectiveness [17][18]. - The company should conduct feasibility studies and risk assessments for significant investment projects [17][18]. Information Disclosure Internal Control - An information disclosure management system must be established to ensure timely and accurate reporting of significant information [19][20]. - The board secretary is responsible for managing external communications and ensuring compliance with disclosure obligations [19][20]. Internal Control Evaluation and Reporting - An internal audit department should be established to oversee the implementation of internal control systems and the accuracy of financial information [26][27]. - The audit committee is responsible for guiding and supervising the internal audit department's work [26][27].

Core Viewpoint - Huasheng Technology (SZ000790) has received an administrative regulatory decision from the Sichuan Securities Regulatory Bureau due to various accounting and internal control issues, leading to a requirement for corrective measures and warnings issued to key executives [2][4][5]. Group 1: Accounting Issues - The company has been found to have irregular accounting practices, including misclassification of advertising expenses as intangible assets by its subsidiary Hainan Rongsheng Hong Technology Co., Ltd. in 2021 [2]. - In 2023, another subsidiary, Tibet Kangyu Pharmaceutical Co., Ltd., recognized revenue from medical device sales without actual transfer of control to customers, leading to subsequent returns [2]. - Additionally, sales expenses from Chengdu Yuanhong Mineral Water Co., Ltd. were incorrectly accounted for in other subsidiaries, affecting performance assessment accuracy [2]. Group 2: Non-operational Fund Occupation - In 2021, Hainan Huasheng Development Holding Co., Ltd., a subsidiary, prepaid non-main business contract funds, which were later returned after five months, during which some funds flowed into companies controlled by the actual controller, constituting non-operational fund occupation [3]. Group 3: Internal Control Deficiencies - The internal control systems of the subsidiaries are inadequate, with issues such as improper expense reimbursement documentation and non-compliance with procurement management protocols [3]. - The company lacks a robust internal control system for large non-main business expenditures, leading to non-operational fund occupation in 2021 [3]. Group 4: Executive Accountability - Key executives, including Huang Mingliang (Chairman and President), Li Jun (Vice President and CFO), and Song Gang (Vice President), have been held responsible for the identified accounting and internal control issues [4][5]. Group 5: Company Performance - In 2024, Huasheng Technology reported revenue of 864 million yuan, a year-on-year decrease of 13.89%, and a net profit attributable to shareholders of -6.69 million yuan, down 124.19% [8]. - In the first quarter of 2025, the company achieved revenue of 127 million yuan, a decline of 29.21%, with a net profit of -14.59 million yuan, a drop of 740.09% year-on-year [9].

Core Points - The supervisory board of Guangzhou Da'an Gene Co., Ltd. held its sixth meeting of the eighth session on March 27, 2025, where several key resolutions were passed [1][2][3] Group 1: Supervisory Board Resolutions - The 2024 Annual Supervisory Board Work Report was approved with a unanimous vote of 5 in favor [1] - The 2024 Annual Financial Settlement Proposal was approved, noting a significant decline in performance due to increased bad debt provisions and a decrease in the fair value of other non-current financial assets [2] - The 2024 Annual Report and its summary were approved, with the supervisory board confirming that the report accurately reflects the company's situation without any misleading statements [2][3] Group 2: Profit Distribution and Financial Management - The 2024 Profit Distribution Proposal was approved, indicating that the company will not distribute cash dividends or issue bonus shares due to negative net profits [3][5] - The 2024 Internal Control Evaluation Report was approved, confirming the effectiveness of the company's internal control system [5][6] - The proposal for expected related party transactions for 2025 was approved, with the supervisory board ensuring compliance with relevant laws and regulations [6][7] Group 3: Financial Management and Policy Changes - The proposal for using idle self-owned funds for cash management in 2025 was approved [7] - The proposal for changes in accounting policies was approved [7]

Meeting Overview - The seventh supervisory board of Zhejiang Dongjing Electronics Co., Ltd. held its eighth meeting on March 21, 2025, with all three supervisors present, including one via telecommunication [1] - The meeting was convened in accordance with relevant laws and regulations, and the voting results were unanimous with 3 votes in favor, 0 against, and 0 abstentions [1] Financial Performance - For the fiscal year 2024, the company reported a revenue of 217.193 million yuan, an increase of 25.37% compared to the previous year [2] - The net profit attributable to shareholders was -73.4534 million yuan, a decrease of 10.30% year-on-year [2] - The net profit after deducting non-recurring gains and losses was -79.0978 million yuan, down 8.73% from the previous year [2] - Total assets at the end of 2024 were reported to have decreased by 23.82% compared to the previous year [2] Profit Distribution Plan - The company proposed not to distribute profits for the fiscal year 2024, which includes no cash dividends, no bonus shares, and no capital reserve conversion [3] - The supervisory board believes this plan aligns with the company's operational situation and future funding arrangements, serving the long-term interests of shareholders [3] Annual Report and Internal Control - The supervisory board confirmed that the procedures for preparing and reviewing the 2024 annual report complied with legal and regulatory requirements, and the report accurately reflects the company's actual situation [3][8] - The internal control self-assessment report for 2024 was deemed to objectively reflect the establishment and operation of the internal control system [8] Financing and Cash Management - The company plans to apply for a total credit limit of up to 300 million yuan from financial institutions for the fiscal year 2025 [5] - The company intends to utilize up to 10 million yuan of idle funds for cash management, investing in low-risk financial products [6][7] Corporate Governance - The supervisory board agreed to continue appointing Lixin Certified Public Accountants as the auditing firm for the fiscal year 2025 [7] - The company plans to purchase liability insurance for directors, supervisors, and senior management to enhance risk control [9] Corporate Restructuring - The company intends to reduce the registered capital of its wholly-owned subsidiary, Zhejiang Hongrui Supply Chain Management Co., Ltd., from 100 million yuan to 1 million yuan [9] - The company also plans to liquidate its wholly-owned subsidiary, Shenzhen Blue Ocean Precision Electronics Technology Co., Ltd. [9]